Tarsus Pharmaceuticals (NASDAQ:TARS) Director Katherine Goodrich Sells 2,954 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Director Katherine Goodrich sold 2,954 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $62.08, for a total transaction of $183,384.32. Following the completion of the sale, the director owned 2,233 shares of the company’s stock, valued at approximately $138,624.64. The trade was a 56.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock opened at $62.55 on Thursday. The firm has a market cap of $2.69 billion, a PE ratio of -54.87 and a beta of 0.49. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.74 and a quick ratio of 3.71. The stock’s fifty day moving average price is $63.47 and its two-hundred day moving average price is $69.54. Tarsus Pharmaceuticals, Inc. has a one year low of $38.51 and a one year high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%.The firm had revenue of $162.05 million during the quarter, compared to the consensus estimate of $149.60 million. As a group, research analysts expect that Tarsus Pharmaceuticals, Inc. will post -0.59 EPS for the current fiscal year.

Institutional Trading of Tarsus Pharmaceuticals

Several large investors have recently made changes to their positions in TARS. Deep Track Capital LP raised its stake in Tarsus Pharmaceuticals by 71.4% during the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $178,290,000 after buying an additional 1,250,000 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Tarsus Pharmaceuticals by 34.1% during the fourth quarter. Janus Henderson Group PLC now owns 1,930,325 shares of the company’s stock valued at $158,062,000 after acquiring an additional 491,326 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Tarsus Pharmaceuticals by 57.5% during the first quarter. Bank of America Corp DE now owns 1,194,377 shares of the company’s stock valued at $83,786,000 after acquiring an additional 436,271 shares in the last quarter. M&T Bank Corp raised its position in shares of Tarsus Pharmaceuticals by 11,730.0% during the fourth quarter. M&T Bank Corp now owns 437,119 shares of the company’s stock worth $35,791,000 after purchasing an additional 433,424 shares during the period. Finally, MPM Bioimpact LLC bought a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter worth $13,834,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Guggenheim lifted their price objective on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Lifesci Capital upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Tuesday, April 21st. Oppenheimer assumed coverage on shares of Tarsus Pharmaceuticals in a research note on Friday, April 24th. They issued an “outperform” rating and a $98.00 price objective on the stock. Finally, Zacks Research downgraded Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Tarsus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $90.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.